Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label multicenter study of TGRX-678 versus investigator-selected tyrosine kinase inhibitor in chronic-phase chronic myeloid leukemia after resistance or intolerance to at least three prior TKIs
CTR20260722Phase 3Active
- Sponsor
- Tajirui
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TGRX-678 in chronic myelogenous leukemia (CML), sponsored by Tajirui. Started Feb 2026; status: active.
02
Drugs
TGRX-678
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on CTR20260722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260722.